Richard Mohs
Direktor/Vorstandsmitglied bei COGSTATE LIMITED
Vermögen: 55 252 $ am 31.05.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Bradley O'Connor | M | - | 20 Jahre | |
| Paul Maruff | M | - | 25 Jahre | |
| Dave Dolby | M | 47 |
Alzheimers Drug Discovery Foundation
 Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | 11 Jahre |
| Richard van den Broek | M | 57 | 14 Jahre | |
| Ingrid Player | F | 50 | 5 Jahre | |
| Katherine Baicker | M | 52 | 13 Jahre | |
| Leonard Lauder | M | 91 |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| William Kaelin | M | 66 | 12 Jahre | |
| Howard Fillit | M | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | 26 Jahre |
| Chris Edgar | M | - | 6 Jahre | |
| Travis Coy | M | 43 | 21 Jahre | |
| Kristi Geddes | F | - | - | |
| Kim Wenn | F | - | 4 Jahre | |
| Jon Fyrwald | M | 63 | 19 Jahre | |
| Ralph Alvarez | M | 68 | 15 Jahre | |
| Marschall Runge | M | 69 | 11 Jahre | |
| Ronald Lauder | M | 80 |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Rachel Colite | F | - | 9 Jahre | |
| Darren Watson | M | - | 3 Jahre | |
| Mark Roithmayr | M | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Edgardo Hernandez | M | - | 19 Jahre | |
| Gary Lauder | M | 61 |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Linda Zambelli | F | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Penny Dacks | F | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Vina Orden | F | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Allison Sawczyn | F | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Nancy Goodes | F | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Alice Shure | F | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Charles Cangro | M | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Elise Lefkowitz | F | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Emilio Matt | M | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Steven Dickman | M | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Larry Kunstadt | M | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Abhishek Agrawal | M | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | 7 Jahre |
| Sara Giesen | F | - | - | |
| Kate Jopling | F | - | 15 Jahre | |
| Kenneth Billard | M | - | 5 Jahre | |
| Nancy Green | F | 62 |
Global Alzheimer's Platform Foundation, Inc.
| - |
| Sally Gilligan | F | 51 |
Global Alzheimer's Platform Foundation, Inc.
| 3 Jahre |
| Arthur Peck | M | 69 |
Global Alzheimer's Platform Foundation, Inc.
| - |
| Sally Susman | F | 62 |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Pascale Witz | F | 57 |
Global Alzheimer's Platform Foundation, Inc.
| 8 Jahre |
| David Weinreb | M | 59 |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Sonia Syngal | F | 54 |
Global Alzheimer's Platform Foundation, Inc.
| - |
| John Keiser | M | 57 |
Global Alzheimer's Platform Foundation, Inc.
| - |
| Martyn Myer | M | 65 | - | |
| John Thomson Wyatt | M | 68 |
Global Alzheimer's Platform Foundation, Inc.
| - |
| Mike Gutch | M | 58 |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Marka Hansen | F | 71 |
Global Alzheimer's Platform Foundation, Inc.
| - |
| Robert J. Heine | M | - | 16 Jahre | |
| Tamara Maes | M | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | 8 Jahre |
| Sabrina Simmons | F | 61 |
Global Alzheimer's Platform Foundation, Inc.
| - |
| Suzanne Grossberg | F | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Stanley P. Raggio | M | 67 |
Global Alzheimer's Platform Foundation, Inc.
| - |
| David Franks | M | 53 | 3 Jahre | |
| Casey Lynch | F | 50 |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Katherine Tsaioun | M | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Katrina O'Connell | F | 54 |
Global Alzheimer's Platform Foundation, Inc.
| - |
| Donald Zakrowski | M | - | 12 Jahre | |
| Roberta Diaz Brinton | M | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 71 | 71,00% |
| Australien | 19 | 19,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Richard Mohs
- Persönliches Netzwerk
